Skip to main content
Premium Trial:

Request an Annual Quote

Analytik Jena Buys Imaging Firm UVP

NEW YORK (GenomeWeb News) – German analytical instrument firm Analytik Jena today announced it signed a contract to acquire life science imaging company UVP for an undisclosed price.

The deal is anticipated to close April 5, and, in addition to acquiring UVP, Analytik Jena will purchase the Upland, Calif.-based company's wholly owned subsidiary Ultra-Violet Products, headquartered in Cambridge, UK.

The deal launches Analytik Jena into the US market, it said.

UVP provides digital imaging systems for applications in proteomics, genomics, and plant and animal sciences. Among the instruments it offers are systems for gel and chemiluminescence imaging, as well as for fluorescent and colorimetric imaging.

The UVP group posted $17.2 million in revenues in 2012 and has 109 employees globally, Analytik Jena said. It anticipates the UVP business' operating results to reach breakeven in the second half of its Fiscal Year 2013. In FY 2014, sales from the business are expected to exceed €40 million ($51.3 million).

The deal follows last week's announcement from Analytik Jena that it launched its French subsidiary Analytik Jena France.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.